New Confidential Risperdal Settlement Reached In Recent Case

November 08, 2016 – – A gynecomastia lawsuit that was due to go to trial in the Court of Common Pleas in Philadelphia, Pennsylvania, has been settled confidentially. Court documents show that the plaintiff, who was seven when prescribed Risperdal for behavioral disorders and Asperger’s syndrome, developed permanent and excessive breast tissue. It was alleged that the manufacturer did not adequately warn of the risk. The settlement is confidential, and neither Janssen Pharmaceuticals, the manufacturer, or its parent company Johnson & Johnson have admitted liability.

“We have been keeping a close eye on proceedings in Pennsylvania in relation to Risperdal,” says a representative from the Risperdal-Settlement.com website. “The settlement will be a relief for the plaintiff, but we must remember many more pending cases are still in the dock as well.”

Some 2,000 product liability claims are included in a mass tort litigation, including the newly settled one. Johnson & Johnson recently reported to the U.S. Securities and Exchange Commission that they are facing at least 13,000 cases at present across the country. So far, there have been five Risperdal settlements in Pennsylvania, with the largest verdict so far, worth $70 million, being awarded to a teenager who was prescribed the drug at age five in 2003, before it had received U.S. Food and Drug Administration approval for pediatric indications.

The second largest verdict in the case, which was one of $2.5 million, happened in February 2015, which was the first gynecomastia trial in Pennsylvania. A month later, a second plaintiff was denied his claim after the jury determined that it was not proven that his breast growth was caused by the drug. However, even in that case they agreed that the safety warnings on the drug were not sufficient.

The third case in Pennsylvania was in November 2015, and the plaintiff was initially awarded $1.75 million, but this was reduced to $680,000 later on. The fourth trial ended a month later, and the plaintiff was awarded $500,000.

Anyone who has been prescribed Risperdal and who believes to have developed gynecomastia (excessive breast tissue growth) as a result of this may be able to file a claim. Risperdal litigation remains ongoing.

###

Contact Drug-Lawsuits.org:

info@drug-lawsuits.org

ReleaseID: 60013085